Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | EED | O75530 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4500350 | 0.91 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3CYP2D6METAP2 | |
| Fumaric Acid SCHEMBL4500346 | 0.91 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3CYP2D6METAP2 | |
| SCHEMBL4498479 | 0.84 | SLC6A2 (0.72) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4476087 | 0.84 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4498669 | 0.84 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4484034 | 0.82 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4481845 | 0.81 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4491214 | 0.81 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL4485584 | 0.79 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4481575 | 0.78 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638934-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005000811-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | claimed |
| US-7619096-B2 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1638934-B1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| EP-1638934-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000811-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | SLC6A2, SLC6A3, SLC18A2 | SLC6A2 1/4885SLC6A4 5/4885SLC6A3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.